UBS Group’s Apogee Therapeutics APGE Stock Holding History

UBS Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-201,831	Closed	-$26.8M	–	11163
2026 Q2	$26.8M	Sell	201,831 -942,497	-82%	-$84.9M	﹤0.01%	2385
2026 Q1	$96.3M	Buy	1,144,328 +169,502	+17%	+$12.3M	0.01%	1080
2025 Q4	$73.6M	Buy	974,826 +175,361	+22%	+$11M	0.01%	1260
2025 Q3	$31.8M	Buy	799,465 +692,308	+646%	+$26.4M	0.01%	2069
2025 Q2	$4.65M	Sell	107,157 -594,752	-85%	-$22.6M	﹤0.01%	3965
2025 Q1	$26.2M	Buy	701,909 +160,623	+30%	+$6.21M	﹤0.01%	2092
2024 Q4	$24.5M	Buy	541,286 +489,466	+945%	+$25M	﹤0.01%	2124
2024 Q3	$3.04M	Buy	51,820 +1,330	+3%	+$63.7K	﹤0.01%	3571
2024 Q2	$1.99M	Sell	50,490 -25,541	-34%	-$1.24M	﹤0.01%	3773
2024 Q1	$5.05M	Buy	+76,031	New	+$3.32M	﹤0.01%	2961
2023 Q4	–	Sell	-3,557	Closed	-$75.8K	–	9271
2023 Q3	$75.8K	Buy	+3,557	New	+$78.4K	﹤0.01%	6025

Other funds holding APGE

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

UBS Group's APGE Position: Q3 2026 in Review

UBS Group sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 201,831 shares — an estimated $26.8M sold.

UBS Group first reported a position in APGE in Q3 2023 and held it in 11 quarters. The position peaked at $96.3M in Q1 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

UBS Group reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
UBS Group sold 201,831 Apogee Therapeutics shares in Q3 2026, an estimated $26.8M.
UBS Group first reported a position in Apogee Therapeutics in Q3 2023 and held it in 11 quarters.
UBS Group's Apogee Therapeutics position peaked at $96.3M in Q1 2026.
2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.